Publications by authors named "Jose Mostazo-Torres"
Following the growing trend of trying to individualise treatment in inflammatory bowel disease and in view of the challenge posed by elderly patients requiring biologic treatments, we have conducted a study in our centre to assess the T3/T4 index as a predictor of response to biologic treatments in elderly patients.
View Article and Find Full Text PDFCrohn's disease of the reservoir is a pathology of difficult diagnosis and complex approach due to the scarce documented evidence on it. Recently, studies have been published on the treatment strategies available for this entity. Based on the above, we have analyzed the experience of our center in the treatment of reservoir Crohn's disease with one of the new biologic agents, ustekinumab.
View Article and Find Full Text PDFArticle Synopsis
- - About 130-170 million people are infected with hepatitis C (HCV), making it a major cause of liver-related deaths and transplants, with antiviral treatments aimed at eradicating the virus.
- - Traditional treatments of pegylated interferon and ribavirin had limited success, particularly in genotypes 1 and 4, prompting the introduction of direct acting antiviral agents (DAAs) in 2011, which improved viral response rates but also came with higher toxicity and costs.
- - The recent development of new DAA therapies since 2013 has led to much higher sustained viral response rates (up to 100%) and less toxicity, although more comprehensive data on their real-world effects are still needed,
Chronic hepatitis B virus (HBV) infection is responsible for up to 30% of cases of liver cirrhosis and up to 53% of cases of hepatocellular carcinoma. Liver transplantation (LT) is the best therapeutic option for patients with end-stage liver failure caused by HBV. The success of transplantation, though, depends on receiving prophylactic treatment against post-transplant viral reactivation.
View Article and Find Full Text PDF